IceCure Medical Ltd., a developer of minimally-invasive cryoablation technology, has announced the expiration and results of its rights offering, raising aggregate gross proceeds of $10 million. The offering, which was approximately two times over-subscribed, allowed holders of the company's ordinary shares to purchase up to 10 million units at a price of $1.00 per unit. The rights offering was conducted under a registration statement on Form F-1, which was declared effective by the U.S. Securities and Exchange Commission $(SEC.UK)$ on July 9, 2025. Maxim Group LLC served as the dealer-manager for the offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.